| Literature DB >> 35509288 |
Bazla Siddiqui1, Asim Ur Rehman1, Ihsan-Ul Haq1, Amal A Al-Dossary2, Abdelhamid Elaissari3, Naveed Ahmed1.
Abstract
Rapid progress in developing multifunctional nanocarriers for drug delivery has been observed in recent years. Inorganic mesoporous silica nanocarriers (MSNs), emerged as an ideal candidate for gene/drug delivery with distinctive morphological features. These ordered carriers of porous nature have gained unique attention due to their distinctive features. Moreover, transformation can be made to these nanocarriers in terms of pores size, pores volume, and particle size by altering specific parameters during synthesis. These ordered porous materials have earned special attention as a drug carrier for treating multiple diseases. Herein, we highlight the strategies employed in synthesizing and functionalizing these versatile nanocarriers. In addition, the various factors that influence their sizes and morphological features were also discussed. The article also summarizes the recent advancements and strategies for drug and gene delivery by rendering smarter MSNs by incorporating functional groups on their surfaces. Averting off-target effects through various capping strategies is a massive milestone for the induction of stimuli-responsive nanocarriers that brings out a great revolution in the biomedical field.Entities:
Keywords: Capping agents; Chemical modification; Gatekeepers; Mesoporous silica nanoparticles; Stimuli-responsive; Targeted drug delivery
Year: 2022 PMID: 35509288 PMCID: PMC9058968 DOI: 10.1016/j.ijpx.2022.100116
Source DB: PubMed Journal: Int J Pharm X ISSN: 2590-1567
Fig. 1Different types of MSNs.
Fig. 2Schematic representation of MCM-41 synthesis using cationic surfactant template.
Distinguishing features of sol-gel and hydrothermal process.
| Distinction | Sol-gel process | Hydrothermal process | References |
|---|---|---|---|
| Process | This process involves two main steps of synthesis, including the formation of particles in solution followed by gel formation due to the 3D polymeric network. | In this process, an inorganic substance is added to the templating agent (acid or alkali), and the fabricated hydrogel is afterward subjected to autoclaving. | ( |
| Reaction conditions | In this process, the requirement of a sealed container is not required. | The reaction takes place in a sealed container, having maintained temperature and pressure. | ( |
| Requirement of Autoclave | The method doesn’t require autoclaving or any other parameter of high temperature. | The method requires a Teflon-lined autoclave to maintain process parameters. | ( |
| Formation of mesoporous particles | Desired morphology is obtained through simultaneous hydrolysis and condensation of metal oxide. | The powdered solid SiO2 got dispersed during heat treatment, and the formation of mesophase assembly occurs after the removal of heat. | ( |
| Morphology of MSNs | Formulation parameters, such as temperature, pH, and reagent concentrations, affect the morphology and size of the particles. | Particle morphology and size have a significant influence on cooling rate after thermal treatment. | ( |
| Advantages | The main advantages include increased purity and ease of synthesis at moderate reaction conditions | The advantage of this method is to obtain of MSNs having greater hydrothermal stability. | ( |
| Disadvantages | The method produces particles in micron size and requires further modifications | The process is complex and requires increased time. | ( |
Fig. 3Strategies utilized for the creation of stimuli-responsive MSNs and their release mechanism.
Fig. 4Stimuli-responsive DNA gated release of drug from MSNs.
Surface modification of MSNs based stimuli-responsive controlled release system of various drugs.
| Chemical modification/functionalization of MSNs | Drug loaded in MSNs | Active stimulus | Effect of functionalization | References |
|---|---|---|---|---|
| Chemical modification of MSNs with Pegylated poly amino acid | Celastrol | pH | Targeted drug delivery to solid cancer by the release of drug at acidic pH, targeted delivery of drug to mitochondria | ( |
| Chemical modification of MSNs with Calcium | siRNA, Chloroquine | pH | Targeted drug delivery to ovarian cancer cells at acidic pH | ( |
| Chemical modification of MSNs with gold nanoparticles- biotin complexes | Doxorubicin | Enzyme | Cytotoxic potential against cells highly expressed with matrix metalloproteinase enzyme | ( |
| Chemical modification of MSNs with quadruplex DNA with stretches of the Cytosine base | Rhodamine | pH | Targeted delivery to cancer cells having acidic pH | ( |
| Chemical modification of MSNs with poly(amidoamine) dendrimer (PAMAM) | Doxorubicin | pH | Increase mucoadhesive properties for bladder cancer therapy, Targeted delivery to cancer cells having acidic pH | ( |
| Chemical modification of MSNs with cytochrome C and aptamer | Doxorubicin | Redox potential | Targeted delivery to a liver tumor (HCT-116 cell lines) having increased GSH concentration | ( |
| Phosphonated MSNs | Ruthenium complexes | Hypoxic condition | Detection and quantification of molecular oxygen with targeted release at a reduced oxygen concentration | ( |
| Chemical modification of MSNs with DNA molecules | Fluorescein | Temperature | Targeted drug delivery upon increased temperature | ( |
| Chemical modification of MSNs with Thymine rich DNA molecules coordinated with mercury (Hg+) ions | Methylene blue | Redox potential | Stimuli-responsive effect of changing in GSH concentration | ( |
| MSNs modified with amino groups | Octahedral Organoruthenim complex | pH | Efficient cytotoxic potential against glioblastoma cells having acidic pH, anti-cancerous activity | ( |
| MSNs Ruthenium polypyridyl complexed DNA | Docetaxel, Paclitaxel | Light | Stimuli-responsive effect to light for the treatment of breast cancer, drug release on application to light | ( |
| MSNs modified with the amino group | Doxorubicin | pH | Efficient cytotoxic potential against non-small cell lung cancer cells having acidic pH | ( |
| MSNs capped with gold nanoparticles and linked with short single-stranded DNA as gatekeeping agent | Doxorubicin | Laser stimulation, pH | Stimuli-responsive effect upon acidic pH and laser stimuli, for treatment of cancer | ( |
| MSNs modified with an amino group | Liraglutide, Fibroblast growth factor 21 | – | Diabetes mellitus type 2 | ( |
| MSNs modified with ruthenium complexes | Safranin O | Light | Photochemical drug delivery system | ( |
| Y-Shaped DNA grafted MSNs | Doxorubicin | ATP | Stimuli-responsive effect to ATP for treatment of cancer | ( |
| Chemical modification of MSNs with Dextrin coupled with Schiff’s base | Doxorubicin hydrochloride | pH | Stimuli-responsive effect to acidic pH for treatment of cancer | ( |
| Chemical modification of MSNs with gold nanoparticles | – | Redox potential | Anti-cancerous activity having increase GSH concentration, by A-549 cells | ( |
| Carboxyl functionalized MSNs capped with cerium oxide nanoparticles | Doxorubicin | pH | Targeted delivery to Hela cells at acidic pH | ( |
| Chemical modification of MSNs with dextrin | Doxorubicin | Enzyme | Anti-cancerous activity with increased penetration having increased concentration of α-amylase enzyme | ( |
| Chemical modification of MSNs with peptide-based amphiphile | Doxorubicin | Redox potential | Targeted drug delivery to tumor cells at increased GSH concentration | ( |
| Chemical modification of MSNs with gelatin | Doxorubicin | pH | Targeted drug delivery to tumor cells at acidic pH | ( |
| Chemical modification of MSNs with Cytosine rich DNA complexed with Ag+ ions | – | Thiol groups | Targeted drug delivery, stimuli-responsive effect to thiol groups | ( |
| Chemical modification of MSNs with gelatin | Doxorubicin | Enzyme | Cytotoxic potential against cells, highly expressed with matrix metalloproteinase enzyme | ( |
| Multifunctional polymer capped MSNs (Chitosan and alginate) | Doxorubicin hydrochloride | pH | Targeted delivery to cancer cells at acidic pH | ( |
| Chitosan capped MSNs linked with glycidoxypropyl-tri-methoxy-silane | Doxorubicin and Pheophorbide | pH | Targeted delivery to cancer cells at acidic pH | ( |
| MSNs modified with dendronized chitosan | Doxorubicin and P-53 gene | Redox potential | Stimuli-responsive effect of increasing GSH concentration for treatment of cancer | ( |
| Gold nanorods coated with MSNs capped with chitosan attached with pH-sensitive variant 7 | Gemcitabine | pH | Targeted delivery to pancreatic tumors Targeted delivery to breast carcinoma cells at acidic pH | ( |
| MSNs coated with chitosan | Raloxifene hydrochloride | pH | Targeted delivery to breast carcinoma cells at acidic pH | ( |
| MSNs modification with 3-triethoxysilylpropylamine (APTES) followed by chitosan modification | Methotrexate | pH | Increase the loading capacity of Methotrexate with more efficient uptake as an anti-cancer agent for breast cancer treatment. Targeted delivery to breast carcinoma cells at acidic pH | ( |
| MSNs modification with dextrin dialdehyde | Doxorubicin | pH | Targeted delivery to cancer at acidic pH | ( |
| Charge reversal MSNs modified by using carboxymethyl/chitosan | Doxorubicin | pH | Targeted delivery to breast carcinoma cells at acidic pH | ( |
| MSNs modification with Fe3O4 nanoparticles | Camptothecin | Magnetic field | Targeted delivery to cancer cells upon application of magnetic field | ( |
| MSNs modification with dopamine modified hyaluronic acid | Doxorubicin | pH | Targeted delivery to mammary carcinoma cells at acidic pH | ( |
| MSNs modification with glucuronic acid-chitosan layer | 5-Fluorouracil | pH | Targeted delivery to colorectal cancer cells at acidic pH | ( |
| MSNs modification with gelatin | Paclitaxel | External magnetic field | Targeted delivery to tumor cells upon application of magnetic field | ( |
| MSNs modification with protamine | Curcumin | Enzyme | Targeted delivery to colorectal cancer cells having protease enzyme | ( |
| Hollow MSNs modification with poly (3-acrylamidophenylboronic acid) (PAPBA) | – | Glucose | Potential use in diabetes treatment, the release of a drug on glucose detection | ( |
| MSNs capped with hyaluronic acid | Doxorubicin | pH | Targeted delivery to Hela cells at acidic pH | ( |
| MSNs capped with hyaluronic acid | 6-mercaptopurine | Redox potential | Targeted delivery to HCT-116 cell lines at increased GSH concentration | ( |
| MSNs modified with multifunctional polymer | – | pH | Targeted delivery to Hela cells upon acidic pH | ( |
| MSNs modified with dialdehyde dextrin | Doxorubicin | pH and Redox potential | On-demand drug delivery to increase GSH concentration and acidic pH to cancer cells | ( |
| MSNs modified with polyethyleneimine | Plasmid DNA | Ultrasound | Drug delivery to cancer cells | ( |
Fig. 5Stimuli responsive gene delivery for cancer therapy.
. Summary of targeting drug delivery system based on MSNs.
| Targeting receptor | Targeting ligand | Target cell type | Refs. |
|---|---|---|---|
| EGFR | Epidermal growth factor | HuH-7 | ( |
| α-Folate receptor | Folic acid | MDA-MB 435 | ( |
| α-Folate receptor | Folic acid | LnCAP | ( |
| Mannose receptor | Mannose | MCF-7, HCT-116, MDA-MB-231 | ( |
| Galactose receptor | Galactose | Hela, A549 | ( |
| Mucin-1 glycoprotein | Mucin-1 antibody | MMT, Mtag | ( |
| CD105 protein | TRC105 antibody | 4T1 | ( |
| CD44 protein | Hyaluronic Acid | MCF-7, MDA-MB-321, 4T1 | ( |
| αvβ3 integrins | cRGD | MDA-MB 435 | ( |
| Transferrin receptor | Transferrin | HepG2 | ( |
Fig. 6MSNs modifications with targeting ligands.